Prescriber Criteria Form

Qinlock 2025 PA Fax 3902-A v1 010125.docx Qinlock (ripretinib) **Coverage Determination**

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673.** Please contact CVS Caremark at 1-866-785-5714 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Qinlock (ripretinib).

Drug Name:

Qinloc	k (ripretinib)				
Patien	t Name:				
Patien	t ID:				
Patien	t DOB:	Patient Phone:			
Presci	riber Name:	·			
Presci	riber Address:				
City:		State:	Zip:		
Presci	riber Phone:	Prescriber Fax:			
Diagn	osis:	ICD Code(s):			
Pleas	se circle the appropriate answer	for each question.			
1	Does the patient have a diagnous [If no, then skip to question 6.]	sis of gastrointestinal stromal t	umor (GIST)?	Yes	No

1	Does the patient have a diagnosis of gastrointestinal stromal tumor (GIST)?	Yes	No
1	[If no, then skip to question 6.]	165	INO
2	Does the patient have residual, unresectable, tumor rupture, advanced, recurrent/metastatic, or progressive disease? [If no, then no further questions.]	Yes	No
3	Has the patient experienced disease progression following treatment with avapritinib and dasatinib? [If yes, then no further questions.]	Yes	No
4	Has the patient received prior treatment with 3 or more kinase inhibitors, including imatinib? [If yes, then no further questions.]	Yes	No
5	Does the patient meet BOTH of the following: A) received prior treatment with imatinib, B) is intolerant to second-line sunitinib? [No further questions.]	Yes	No
6	Does the patient have a diagnosis of cutaneous melanoma? [If no, then no further questions.]	Yes	No
7	Does the patient meet ALL of the following: A) disease is metastatic or unresectable, B) disease is positive for KIT activating mutations, C) patient has experienced disease	Yes	No

8 Will the requested drug be used as subsequent therapy?